Paclitaxel releasing balloon - BIOTRONIK

Drug Profile

Paclitaxel releasing balloon - BIOTRONIK

Alternative Names: Drug-eluting balloon - BIOTRONIK; Pantera Lux Paclitaxel Releasing Balloon; Passeo-18 Lux; Passeo-18 Lux DCB

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIOTRONIK
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • No development reported Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 06 Sep 2017 No development reported - Phase-II for Ischaemic heart disorders in Australia (Intracoronary)
  • 06 Sep 2017 No development reported - Phase-II for Peripheral arterial disorders in Belgium, Germany, Austria (Intra-arterial)
  • 22 Sep 2016 Biotronik Medical Device plans the phase III BIOLUX-P IV CHINA trial for Peripheral arterial disorders in China (Intra-arterial) (NCT02912715)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top